Skip to main content

Table 1 Patient and tumor characteristics

From: Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group

Characteristics

n = 41

Gender

 

  Male

29 (71%)

  Female

12 (29%)

Age (years)

 

  Median (min-max)

60 (33-82)

ECOG

 

  0/1

16/15 (98%)

Symptoms-Clinical manifestations

 

  Abdominal pain

9 (22%)

  Constipation

4 (10%)

  Rectal bleeding

5 (12%)

  Accidental discovery

9 (22%)

  Others (genito urinary, pelvic heaviness)

6 (15%)

  Unknown

8 (19%)

Tumor characteristics

 

  Tumor location

 

  Rectum (Middle third/Lower third)

9/22 (24/50%)

  Pararectal space

7 (17%)

  Unspecified

3 (9%)

  Tumor size (mm)

 

  median (min-max)

62 (6-130)

Evaluated by:

 

  Abdominopelvic CT Scan

21 (51%)

  MRI

18 (44%)

  Endosonography

23 (56%)

  Unknown

6 (14%)

Histology/Genotype/risk

 

  CD117+

34 (83%)

  CD34+

 

  Mitotic index

 

  ≤ 5/50 HPF

11 (27%)

  > 5/50 HPF

21 (51%)

  Unknown

9 (22%)

Mutation status (done on 12 cases)

KIT Exon 11 mutation in 10/12

KIT Exon 9 mutation in 1/12

KIT Exon 17 mutation in 1/12

None PDGFRA mutation

NIH risk categories

 

  Very low risk

3 (7%)

  Low risk

3 (7%)

  Intermediate risk

6 (14%)

  High risk

18 (42%)

Miettinen risk categories

 

  None risk

3 (7%)

  Low risk

4 (10%)

  High risk

23 (56%)

  Insufficient data (unclassified)

11 (26%)